Navigating 4 Analyst Ratings For Pacira BioSciences
Portfolio Pulse from Benzinga Insights
Analysts have provided varied ratings for Pacira BioSciences (NASDAQ:PCRX) over the past three months, with a recent shift towards a more bullish stance. The average 12-month price target has been adjusted to $47.25, marking a 10.85% decrease. The company faces revenue challenges with a -2.11% decline over 3 months but exhibits strong financial health with exceptional net margin and ROE. Pacira BioSciences specializes in non-opioid pain management solutions, notably EXPAREL.
March 01, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Pacira BioSciences has seen a mix of analyst ratings with a recent bullish trend. The average price target was reduced to $47.25. The company reported a revenue decline but maintains strong profitability metrics.
The mixed analyst ratings with a recent bullish trend suggest uncertainty but potential optimism about PCRX's future performance. The reduction in the average price target reflects caution, while the company's strong profitability metrics indicate underlying financial health. The revenue decline is a concern but may be offset by the company's strong net margin and ROE.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100